Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution

被引:42
作者
Ogura, Kengo [1 ,2 ]
Mizowaki, Takashi [1 ,2 ]
Arakawa, Yoshiki [3 ]
Ogura, Masakazu [1 ,2 ]
Sakanaka, Katsuyuki [1 ,2 ]
Miyamoto, Susumu [3 ]
Hiraoka, Masahiro [1 ,2 ]
机构
[1] Dept Radiat Oncol, Shogoin Sakyo Ku, Kyoto 6068507, Japan
[2] Dept Image Appl Therapy, Shogoin Sakyo Ku, Kyoto 6068507, Japan
[3] Kyoto Univ, Grad Sch Med, Kyoto 6068507, Japan
来源
RADIATION ONCOLOGY | 2013年 / 8卷
关键词
Glioblastoma; Recurrence patterns; Temozolomide; Radiotherapy; RANO criteria; Salvage treatment; RADIOTHERAPY PLUS CONCOMITANT; RESPONSE CRITERIA; MALIGNANT GLIOMA; PSEUDOPROGRESSION; MULTIFORME; ADJUVANT; FAILURE; RADIATION;
D O I
10.1186/1748-717X-8-97
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy. Methods: Twenty-one patients with glioblastoma that recurred after concurrent temozolomide and localized radiotherapy were retrospectively analyzed (11 male, 10 female; median age, 57 years; range, 27-74). Disease progression was assessed by new response criteria proposed by the Response Assessment in Neuro-Oncology Working Group of the American Society of Clinical Oncology. The pattern of recurrence was determined by relationships between locations of recurrent tumors and irradiated doses. Central, in-field, marginal, and out-field recurrences were defined relative to the prescribed isodose line. Distant recurrence was operationally defined as subependymal or disseminated disease. Initial and cumulative patterns of recurrence were evaluated in each patient. Results: The median follow-up of the recurrent patients was 501 (range, 217-1815) days after initial surgery. Initial recurrences were central in 14 patients (66.7%), in-field in four patients (19.0%), marginal in no patient (0%), outfield in two patients (9.5%), and distant in four patients (19.0%). One patient had both central and in-field recurrences simultaneously, and two had both central and distant recurrences. In the analysis of cumulative recurrence patterns, five patients, who had no scans after initial recurrences, were excluded and the remaining 16 were included. Cumulative recurrences were central in 11 patients (68.8%), in-field in five patients (31.3%), marginal in three patients (18.8%), out-field in five patients (31.3%), and distant in 14 patients (87.5%). Regarding salvage treatments, 11 (52.4%), 11 (52.4%) and 17 (81.0%) patients underwent surgery, stereotactic radiotherapy and chemotherapy, respectively. Eighteen (85.7%) patients had died at the time of analysis, and 16 of them (88.9%) had suffered distant recurrences, which could have been the immediate causes of death. Conclusions: Recurrence patterns of glioblastoma after radiotherapy plus concomitant and adjuvant temozolomide were mainly central at first, and distant recurrences were often detected during the clinical course. Much better local control and prevention of distant recurrence, including effective salvage treatment, seem to be important.
引用
收藏
页数:9
相关论文
共 20 条
  • [1] Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme Clinical article
    Aoki, Tomokazu
    Mizutani, Tomohiko
    Nojima, Kuniharu
    Takagi, Takehisa
    Okumura, Ryosuke
    Yuba, Yoshiaki
    Ueba, Tetsuya
    Takahashi, Jun A.
    Miyatake, Shin-Ichi
    Nozaki, Kazuhiko
    Taki, Waro
    Matsutani, Masao
    [J]. JOURNAL OF NEUROSURGERY, 2010, 112 (01) : 50 - 56
  • [2] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Brandes, Alba A.
    Franceschi, Enrico
    Tosoni, Alicia
    Blatt, Valeria
    Pession, Annalisa
    Tallini, Giovanni
    Bertorelle, Roberta
    Bartolini, Stefania
    Calbucci, Fabio
    Andreoli, Alvaro
    Frezza, Giampiero
    Leonardi, Marco
    Spagnolli, Federica
    Ermani, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2192 - 2197
  • [3] Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
    Brandes, Alba A.
    Tosoni, Alicia
    Franceschi, Enrico
    Sotti, Guido
    Frezza, Giampiero
    Amista, Pietro
    Morandi, Luca
    Spagnolli, Federica
    Ermani, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1275 - 1279
  • [4] Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
    Brandsma, Dieto
    Stalpers, Lukas
    Taal, Walter
    Sminia, Peter
    van den Bent, Martinj
    [J]. LANCET ONCOLOGY, 2008, 9 (05) : 453 - 461
  • [5] Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma
    Chang, Eric L.
    Akyurek, Serap
    Avalos, Tedde
    Rebueno, Neal
    Spicer, Chris
    Garcia, John
    Famiglietti, Robin
    Allen, Pamela K.
    Chao, K. S. Clifford
    Mahajan, Anita
    Woo, Shiao Y.
    Maor, Moshe H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (01): : 144 - 150
  • [6] Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide
    Dobelbower, Michael C.
    Burnett, Omer L., III
    Nordal, Robert A.
    Nabors, Louis B.
    Markert, James M.
    Hyatt, Mark D.
    Fiveash, John B.
    [J]. JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2011, 55 (01) : 77 - 81
  • [7] Ghose A, 2010, CURR ONCOL, V17, P52
  • [8] Brain tumor imaging in clinical trials
    Henson, J. W.
    Ulmer, S.
    Harris, G. J.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2008, 29 (03) : 419 - 424
  • [9] RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA
    MACDONALD, DR
    CASCINO, TL
    SCHOLD, SC
    CAIRNCROSS, JG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1277 - 1280
  • [10] McDonald MW, 2011, INT J RADIAT ONCOL, V79, P130, DOI 10.1016/j.ijrobp.2009.10.048